Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified low-dose cytarabine vs hypomethylating agent in elderly AML unfit for intensive chemotherapy
KCT0001891Phase 3Recruiting
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Seoul St. Mary's Hospital. Started Apr 2016; status: recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0001891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001891.